Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

Priyanka  Duttagupta; Kiranj  Chaudagar; Sweta Sharma Saha; Kaela  Bynoe; Eileen  Parkes; Akash Patnaik

doi:10.1158/1535-7163.TARG-19-LB-B03

Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

Priyanka Duttagupta, Kiranj Chaudagar, Sweta Sharma Saha, Kaela Bynoe, Eileen Parkes, Akash Patnaik

Research output: Contribution to journal › Conference article › peer-review

Abstract

While immune checkpoint blockade (ICB) targeting CTLA-4 and PD-1/PD-L1 has shown remarkable success across a wide range of malignancies, the majority of prostate cancer (PC) patients do not demonstrate clinically meaningful responses to these therapies. Therefore, there is a critical unmet need to discover combinatorial therapeutic strategies that enhance immune-responsiveness in ICB-refractory cancers, such as PC.

Original language	English
Journal	Molecular Cancer Therapeutics
Volume	18
Issue number	12_Supplement
DOIs	https://doi.org/10.1158/1535-7163.TARG-19-LB-B03
Publication status	Published - 2 Dec 2019
Externally published	Yes
Event	AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 - Boston, United States Duration: 26 Oct 2019 → 30 Oct 2019

Access to Document

10.1158/1535-7163.TARG-19-LB-B03

Cite this

Duttagupta, P., Chaudagar, K., Sharma Saha, S., Bynoe, K., Parkes, E., & Patnaik, A. (2019). Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages. Molecular Cancer Therapeutics, 18(12_Supplement). https://doi.org/10.1158/1535-7163.TARG-19-LB-B03

@article{c7577aedfc33468ca277a4a400945739,

title = "Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages",

abstract = "While immune checkpoint blockade (ICB) targeting CTLA-4 and PD-1/PD-L1 has shown remarkable success across a wide range of malignancies, the majority of prostate cancer (PC) patients do not demonstrate clinically meaningful responses to these therapies. Therefore, there is a critical unmet need to discover combinatorial therapeutic strategies that enhance immune-responsiveness in ICB-refractory cancers, such as PC.",

author = "Priyanka Duttagupta and Kiranj Chaudagar and {Sharma Saha}, Sweta and Kaela Bynoe and Eileen Parkes and Akash Patnaik",

year = "2019",

month = dec,

day = "2",

doi = "10.1158/1535-7163.TARG-19-LB-B03",

language = "English",

volume = "18",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "12_Supplement",

note = "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 ; Conference date: 26-10-2019 Through 30-10-2019",

}

Duttagupta, P, Chaudagar, K, Sharma Saha, S, Bynoe, K, Parkes, E & Patnaik, A 2019, 'Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages', Molecular Cancer Therapeutics, vol. 18, no. 12_Supplement. https://doi.org/10.1158/1535-7163.TARG-19-LB-B03

Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages. / Duttagupta, Priyanka ; Chaudagar, Kiranj ; Sharma Saha, Sweta et al.
In: Molecular Cancer Therapeutics, Vol. 18, No. 12_Supplement, 02.12.2019.

Research output: Contribution to journal › Conference article › peer-review

TY - JOUR

T1 - Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

AU - Duttagupta, Priyanka

AU - Chaudagar, Kiranj

AU - Sharma Saha, Sweta

AU - Bynoe, Kaela

AU - Parkes, Eileen

AU - Patnaik, Akash

PY - 2019/12/2

Y1 - 2019/12/2

N2 - While immune checkpoint blockade (ICB) targeting CTLA-4 and PD-1/PD-L1 has shown remarkable success across a wide range of malignancies, the majority of prostate cancer (PC) patients do not demonstrate clinically meaningful responses to these therapies. Therefore, there is a critical unmet need to discover combinatorial therapeutic strategies that enhance immune-responsiveness in ICB-refractory cancers, such as PC.

AB - While immune checkpoint blockade (ICB) targeting CTLA-4 and PD-1/PD-L1 has shown remarkable success across a wide range of malignancies, the majority of prostate cancer (PC) patients do not demonstrate clinically meaningful responses to these therapies. Therefore, there is a critical unmet need to discover combinatorial therapeutic strategies that enhance immune-responsiveness in ICB-refractory cancers, such as PC.

UR - https://mct.aacrjournals.org/content/18/12_Supplement/LB-B03.abstract

U2 - 10.1158/1535-7163.TARG-19-LB-B03

DO - 10.1158/1535-7163.TARG-19-LB-B03

M3 - Conference article

SN - 1535-7163

VL - 18

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 12_Supplement

T2 - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019

Y2 - 26 October 2019 through 30 October 2019

ER -

Abstract LB-B03: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

Abstract

Access to Document

Other files and links

Fingerprint

Cite this